市場調査レポート
商品コード
1441324
多発性骨髄腫治療の世界市場規模、シェア、成長分析、治療タイプ別、流通チャネル別-産業予測、2023~2030年Global Multiple Myeloma Therapeutics Market Size, Share, Growth Analysis, By Treatment type, By Distribution Channel - Industry Forecast 2023-2030 |
多発性骨髄腫治療の世界市場規模、シェア、成長分析、治療タイプ別、流通チャネル別-産業予測、2023~2030年 |
出版日: 2024年02月17日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
|
多発性骨髄腫治療の世界市場規模は2022年に266億9,000万米ドルと評価され、2023年の284億2,000万米ドルから2031年には470億4,000万米ドルに成長し、予測期間(2024~2031年)のCAGRは6.5%で成長する展望です。
多発性骨髄腫治療の世界市場は、近年、いくつかの重要な要因によって著しい成長を遂げています。骨髄機能を破壊し、形質細胞の異常増殖と骨の脆弱化をもたらすこの複雑な血液がんは、人口の高齢化と世界の医療コミュニティにおける分子メカニズムに対する理解の深まりにより、注目度が高まっています。科学研究の進歩は、幹細胞移植、免疫調節薬、プロテアソーム阻害薬、化学療法、モノクローナル抗体、支持療法などの標的治療法の開発に道を開いた。製薬会社は新規治療や個別化医療アプローチに多額の投資を行い、業界の競合を激化させています。製薬会社、バイオテクノロジー企業、研究機関の協力により、モノクローナル抗体やCAR-T細胞療法など、有効性が向上し副作用が軽減された革新的な治療法が生まれ、治療法の選択肢が大きく飛躍する兆しを見せています。
エグゼクティブサマリー
Global Multiple Myeloma Therapeutics Market size was valued at USD 26.69 billion in 2022 and is poised to grow from USD 28.42 billion in 2023 to USD 47.04 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).
The global market for multiple myeloma therapeutics has experienced remarkable growth in recent years, driven by several key factors. This complex hematological cancer, which disrupts bone marrow function and leads to abnormal plasma cell proliferation and bone fragility, has seen increased attention due to the aging population and a greater understanding of its molecular mechanisms within the global health community. Advances in scientific research have paved the way for the development of targeted therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, chemotherapy, monoclonal antibodies, and supportive care measures. Pharmaceutical companies are heavily investing in novel treatments and personalized care approaches, intensifying competition in the industry. Collaborations between pharmaceutical firms, biotech companies, and research institutions have yielded innovative therapies with improved efficacy and reduced side effects, such as monoclonal antibodies and CAR-T cell therapies, heralding a significant leap forward in treatment options.
Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Myeloma Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Multiple Myeloma Therapeutics Market Segmental Analysis
By Treatment type, the market is segmented into Chemotherapy and other drugs, Traditional chemotherapy, Immunomodulating agents, Proteasome inhibitors, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Radiation, Stem cell transplant and supportive treatment. Retail Pharmacies & Drug Stores, Hospital Pharmacies and Online Pharmacies are the market segments we end up with when division by distribution channel occurs. If we split the market by region, we will be left with the following sectors: North America, Middle East and Africa, Europe, Asia Pacific, and Latin America.
Drivers of the Multiple Myeloma Therapeutics Market
Advancements in Treatment Options have significantly propelled the multiple myeloma therapeutics market forward, with the introduction of innovative medications such as monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs). These novel therapies, designed to target cancer cells while minimizing harm to healthy cells, have substantially enhanced treatment efficacy, prolonged patient survival rates, and enhanced post-therapy quality of life. Additionally, the Growing Aging Population has contributed to the market's expansion, as older individuals are more susceptible to multiple myeloma, thus increasing demand for efficient treatment options
Restraints in the Multiple Myeloma Therapeutics Market
High Treatment Costs present a notable restraint, as some therapies remain prohibitively expensive, particularly in regions with limited access to healthcare or lower economic status, potentially limiting the adoption of advanced treatments. Moreover, the Complex Disease Characteristics of multiple myeloma, including its genetic and molecular heterogeneity, pose challenges in developing personalized treatment plans tailored to individual patient needs, which could impede the market's growth.
Market Trends of the Multiple Myeloma Therapeutics Market
Key Market Trends include the ongoing focus on Advancements in Targeted Therapies and Immunotherapies, aiming to minimize the side effects associated with traditional chemotherapy by directly targeting cancer cells. Additionally, there's a growing emphasis on Personalized Medicine and Biomarker-driven Approaches, leveraging genetic profiling and biomarkers to identify patient subgroups most likely to benefit from specific treatments, thus optimizing therapeutic outcomes.
Executive Summary